APO Research
Talk to an analyst

APO RESEARCH · REPORT

Niraparib

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Niraparib Market Outlook and Growth Opportunities 2026

23 December 2025193 pages

Choose your research edition.

Industry ResearchNiraparib Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Niraparib Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal Niraparib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Niraparib Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Niraparib Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Niraparib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Niraparib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Niraparib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Niraparib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Niraparib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Niraparib market include TESARO and Everest Pharmaceuticals Limited among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Niraparib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Niraparib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Niraparib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Niraparib market size, projected growth trends, production technologies, key applications, and end-use industries.

Niraparib Segment by Company

TESARO

Everest Pharmaceuticals Limited

Niraparib Segment by Type

100mg*30 Capsules

100mg*60 Capsules

100mg*90 Capsules

Niraparib Segment by Application

Primary Peritoneal Cancer

Fallopian Tube Cancer

Recurrent Epithelial Ovarian Cancer

Others

Niraparib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Niraparib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Niraparib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Niraparib significant trends, drivers, influence factors in global and regions.

6. To analyze Niraparib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Niraparib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Niraparib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Niraparib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Niraparib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Niraparib industry.

Chapter 3: Detailed analysis of Niraparib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Niraparib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Niraparib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Niraparib Industry Trends Table 2. Niraparib Industry Drivers Table 3. Niraparib Industry Opportunities and Challenges Table 4. Niraparib Industry Restraints Table 5. Global Niraparib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Niraparib Revenue Share by Company (2021-2026) Table 7. Global Niraparib Sales Volume by Company (k pcs) & (2021-2026) Table 8. Global Niraparib Sales Volume Share by Company (2021-2026) Table 9. Global Niraparib Average Price (US$/pcs) of Company (2021-2026) Table 10. Global Niraparib Company Ranking, (2024-2026) & (USD Million) Table 11. Global Niraparib Key Company Manufacturing Base & Headquarters Table 12. Global Niraparib Company, Product Type & Application Table 13. Global Niraparib Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Niraparib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 100mg*30 Capsules Table 18. Significant Companies of 100mg*60 Capsules Table 19. Significant Companies of 100mg*90 Capsules Table 20. Global Niraparib Sales Volume by Type 2021 VS 2025 VS 2032 (k pcs) Table 21. Global Niraparib Sales Volume by Type (2021-2026) & (k pcs) Table 22. Global Niraparib Sales Volume by Type (2027-2032) & (k pcs) Table 23. Global Niraparib Sales Volume Share by Type (2021-2026) Table 24. Global Niraparib Sales Volume Share by Type (2027-2032) Table 25. Global Niraparib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Niraparib Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Niraparib Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Niraparib Sales Value Share by Type (2021-2026) Table 29. Global Niraparib Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Primary Peritoneal Cancer Table 31. Significant Companies of Fallopian Tube Cancer Table 32. Significant Companies of Recurrent Epithelial Ovarian Cancer Table 33. Significant Companies of Others Table 34. Global Niraparib Sales Volume by Application 2021 VS 2025 VS 2032 (k pcs) Table 35. Global Niraparib Sales Volume by Application (2021-2026) & (k pcs) Table 36. Global Niraparib Sales Volume by Application (2027-2032) & (k pcs) Table 37. Global Niraparib Sales Volume Share by Application (2021-2026) Table 38. Global Niraparib Sales Volume Share by Application (2027-2032) Table 39. Global Niraparib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Niraparib Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Niraparib Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Niraparib Sales Value Share by Application (2021-2026) Table 43. Global Niraparib Sales Value Share by Application (2027-2032) Table 44. Global Niraparib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 45. Global Niraparib Sales by Region (2021-2026) & (k pcs) Table 46. Global Niraparib Sales Market Share by Region (2021-2026) Table 47. Global Niraparib Sales by Region (2027-2032) & (k pcs) Table 48. Global Niraparib Sales Market Share by Region (2027-2032) Table 49. Global Niraparib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Niraparib Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Niraparib Sales Value Share by Region (2021-2026) Table 52. Global Niraparib Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Niraparib Sales Value Share by Region (2027-2032) Table 54. Global Niraparib Market Average Price (US$/pcs) by Region (2021-2026) Table 55. Global Niraparib Market Average Price (US$/pcs) by Region (2027-2032) Table 56. Global Niraparib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Table 57. Global Niraparib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Niraparib Sales by Country (2021-2026) & (k pcs) Table 59. Global Niraparib Sales Market Share by Country (2021-2026) Table 60. Global Niraparib Sales by Country (2027-2032) & (k pcs) Table 61. Global Niraparib Sales Market Share by Country (2027-2032) Table 62. Global Niraparib Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Niraparib Sales Value Market Share by Country (2021-2026) Table 64. Global Niraparib Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Niraparib Sales Value Market Share by Country (2027-2032) Table 66. TESARO Company Information Table 67. TESARO Business Overview Table 68. TESARO Niraparib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 69. TESARO Niraparib Product Portfolio Table 70. TESARO Recent Development Table 71. Everest Pharmaceuticals Limited Company Information Table 72. Everest Pharmaceuticals Limited Business Overview Table 73. Everest Pharmaceuticals Limited Niraparib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 74. Everest Pharmaceuticals Limited Niraparib Product Portfolio Table 75. Everest Pharmaceuticals Limited Recent Development Table 76. Key Raw Materials Table 77. Raw Materials Key Suppliers Table 78. Niraparib Distributors List Table 79. Niraparib Customers List Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. Niraparib Product Image Figure 2. Global Niraparib Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Niraparib Sales Value (2021-2032) & (US$ Million) Figure 4. Global Niraparib Sales (2021-2032) & (k pcs) Figure 5. Global Niraparib Sales Average Price (US$/pcs) & (2021-2032) Figure 6. Global Niraparib Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 100mg*30 Capsules Image Figure 10. 100mg*60 Capsules Image Figure 11. 100mg*90 Capsules Image Figure 12. Global Niraparib Sales Volume by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 13. Global Niraparib Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Niraparib Sales Volume Share by Type (2021-2032) Figure 15. Global Niraparib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Niraparib Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Niraparib Sales Value Share by Type (2021-2032) Figure 18. Primary Peritoneal Cancer Image Figure 19. Fallopian Tube Cancer Image Figure 20. Recurrent Epithelial Ovarian Cancer Image Figure 21. Others Image Figure 22. Global Niraparib Sales Volume by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 23. Global Niraparib Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Niraparib Sales Volume Share by Application (2021-2032) Figure 25. Global Niraparib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Niraparib Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Niraparib Sales Value Share by Application (2021-2032) Figure 28. Global Niraparib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 29. Global Niraparib Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Niraparib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Niraparib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Niraparib Sales Value (2021-2032) & (US$ Million) Figure 33. North America Niraparib Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Niraparib Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Niraparib Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Niraparib Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Niraparib Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Niraparib Sales Value (2021-2032) & (US$ Million) Figure 39. South America Niraparib Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Niraparib Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Niraparib Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Niraparib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Niraparib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Niraparib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Niraparib Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Niraparib Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg*30 Capsules
  • 100mg*60 Capsules
  • 100mg*90 Capsules
Applications
  • Primary Peritoneal Cancer
  • Fallopian Tube Cancer
  • Recurrent Epithelial Ovarian Cancer
  • Others
Companies covered
  • TESARO
  • Everest Pharmaceuticals Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Niraparib Sales Value (2021-2032)
  4. 1.2.2 Global Niraparib Sales Volume (2021-2032)
  5. 1.2.3 Global Niraparib Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Niraparib Market Dynamics
  1. 2.1 Niraparib Industry Trends
  2. 2.2 Niraparib Industry Drivers
  3. 2.3 Niraparib Industry Opportunities and Challenges
  4. 2.4 Niraparib Industry Restraints
3 Niraparib Market by Company
  1. 3.1 Global Niraparib Company Revenue Ranking in 2025
  2. 3.2 Global Niraparib Revenue by Company (2021-2026)
  3. 3.3 Global Niraparib Sales Volume by Company (2021-2026)
  4. 3.4 Global Niraparib Average Price by Company (2021-2026)
  5. 3.5 Global Niraparib Company Ranking (2024-2026)
  6. 3.6 Global Niraparib Company Manufacturing Base and Headquarters
  7. 3.7 Global Niraparib Company Product Type and Application
  8. 3.8 Global Niraparib Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Niraparib Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Niraparib Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Niraparib Market by Type
  1. 4.1 Niraparib Type Introduction
  2. 4.1.1 100mg*30 Capsules
  3. 4.1.2 100mg*60 Capsules
  4. 4.1.3 100mg*90 Capsules
  5. 4.2 Global Niraparib Sales Volume by Type
  6. 4.2.1 Global Niraparib Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Niraparib Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Niraparib Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Niraparib Sales Value by Type
  10. 4.3.1 Global Niraparib Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Niraparib Sales Value by Type (2021-2032)
  12. 4.3.3 Global Niraparib Sales Value Share by Type (2021-2032)
5 Niraparib Market by Application
  1. 5.1 Niraparib Application Introduction
  2. 5.1.1 Primary Peritoneal Cancer
  3. 5.1.2 Fallopian Tube Cancer
  4. 5.1.3 Recurrent Epithelial Ovarian Cancer
  5. 5.1.4 Others
  6. 5.2 Global Niraparib Sales Volume by Application
  7. 5.2.1 Global Niraparib Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Niraparib Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Niraparib Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Niraparib Sales Value by Application
  11. 5.3.1 Global Niraparib Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Niraparib Sales Value by Application (2021-2032)
  13. 5.3.3 Global Niraparib Sales Value Share by Application (2021-2032)
6 Niraparib Regional Sales and Value Analysis
  1. 6.1 Global Niraparib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Niraparib Sales by Region (2021-2032)
  3. 6.2.1 Global Niraparib Sales by Region: 2021-2026
  4. 6.2.2 Global Niraparib Sales by Region (2027-2032)
  5. 6.3 Global Niraparib Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Niraparib Sales Value by Region (2021-2032)
  7. 6.4.1 Global Niraparib Sales Value by Region: 2021-2026
  8. 6.4.2 Global Niraparib Sales Value by Region (2027-2032)
  9. 6.5 Global Niraparib Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Niraparib Sales Value (2021-2032)
  12. 6.6.2 North America Niraparib Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Niraparib Sales Value (2021-2032)
  15. 6.7.2 Europe Niraparib Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Niraparib Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Niraparib Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Niraparib Sales Value (2021-2032)
  21. 6.9.2 South America Niraparib Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Niraparib Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Niraparib Sales Value Share by Country, 2025 VS 2032
7 Niraparib Country-level Sales and Value Analysis
  1. 7.1 Global Niraparib Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Niraparib Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Niraparib Sales by Country (2021-2032)
  4. 7.3.1 Global Niraparib Sales by Country (2021-2026)
  5. 7.3.2 Global Niraparib Sales by Country (2027-2032)
  6. 7.4 Global Niraparib Sales Value by Country (2021-2032)
  7. 7.4.1 Global Niraparib Sales Value by Country (2021-2026)
  8. 7.4.2 Global Niraparib Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Niraparib Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Niraparib Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Niraparib Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Niraparib Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Niraparib Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Niraparib Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Niraparib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Niraparib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Niraparib Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Niraparib Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Niraparib Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Niraparib Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Niraparib Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Niraparib Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Niraparib Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Niraparib Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Niraparib Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Niraparib Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Niraparib Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Niraparib Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Niraparib Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Niraparib Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Niraparib Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Niraparib Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Niraparib Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Niraparib Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Niraparib Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Niraparib Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Niraparib Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Niraparib Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Niraparib Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Niraparib Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Niraparib Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Niraparib Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Niraparib Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Niraparib Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Niraparib Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Niraparib Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Niraparib Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Niraparib Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Niraparib Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Niraparib Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Niraparib Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Niraparib Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Niraparib Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Niraparib Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Niraparib Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Niraparib Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Niraparib Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Niraparib Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Niraparib Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Niraparib Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Niraparib Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Niraparib Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Niraparib Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Niraparib Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Niraparib Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Niraparib Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Niraparib Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Niraparib Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Niraparib Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Niraparib Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Niraparib Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Niraparib Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Niraparib Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Niraparib Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Niraparib Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Niraparib Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Niraparib Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Niraparib Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Niraparib Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Niraparib Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Niraparib Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Niraparib Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Niraparib Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Niraparib Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Niraparib Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Niraparib Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Niraparib Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Niraparib Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Niraparib Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Niraparib Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Niraparib Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Niraparib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 TESARO
  2. 8.1.1 TESARO Company Information
  3. 8.1.2 TESARO Business Overview
  4. 8.1.3 TESARO Niraparib Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 TESARO Niraparib Product Portfolio
  6. 8.1.5 TESARO Recent Developments
  7. 8.2 Everest Pharmaceuticals Limited
  8. 8.2.1 Everest Pharmaceuticals Limited Company Information
  9. 8.2.2 Everest Pharmaceuticals Limited Business Overview
  10. 8.2.3 Everest Pharmaceuticals Limited Niraparib Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Everest Pharmaceuticals Limited Niraparib Product Portfolio
  12. 8.2.5 Everest Pharmaceuticals Limited Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Niraparib Value Chain Analysis
  2. 9.1.1 Niraparib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Niraparib Sales Mode & Process
  6. 9.2 Niraparib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Niraparib Distributors
  9. 9.2.3 Niraparib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst